['non-small cell lung cancer', 'malignant pleural effusion']
['bevacizumab']

        Inclusion Criteria:

          1. Histological or cytological diagnosis of non-small cell lung cancer.

          2. Cytological diagnosis of malignant pleural or pericardial effusion (MPE)

          3. Symptomatic MPE evaluated by researchers

          4. Unsuitable for or reject systemic therapy of tumor

          5. Estimated survival of more than 3 months. 6.18 years or older

        Exclusion Criteria:

          1. Current or recent (within 10 days prior to treatment) use the full amount of
             inhibition of platelet function, anticoagulants or thrombolytic therapy, which allows
             prophylactic anticoagulants

          2. Be allergic to bevacizumab

          3. Pregnant or lactating woman

          4. Pleural or pericardial infection
      